Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BTIG Downgrades Redwood Trust to Neutral

BTIG analyst Eric Hagen downgrades Redwood Trust (NYSE:RWT) from Buy to Neutral.

byBenzinga Newsdesk

August 31, 2022

1 minute read

BTIG analyst Eric Hagen downgrades Redwood Trust (NYSE:RWT) from Buy to Neutral.

Apollo Endosurgery’s New Obesity Endoscopic Systems Receive FDA Nod

By Vandana Singh

Today, 6:06 PM

Apollo Endosurgery Inc (NASDAQ:APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx…

APEN

Immutep Announces GMP Manufacturing Process Developed For IMP761, A First-in-Class LAG-3 Agonist For Autoimmune Disease

By Benzinga Newsdesk

Today, 6:06 PM

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced

IMMP

Canaccord Genuity Maintains Buy on Open Lending, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 6:06 PM

Canaccord Genuity analyst Joseph Vafi maintains Open Lending (NASDAQ:LPRO) with a Buy and lowers the price target from $55 to $30.

LPRO

Morgan Stanley Maintains Overweight on Take-Two Interactive, Lowers Price Target to $195

By Benzinga Newsdesk

Today, 6:06 PM

Morgan Stanley analyst Brian Nowak maintains Take-Two Interactive (NASDAQ:TTWO) with a Overweight and lowers the price target from $215 to $195.

TTWO

BTIG Downgrades Redwood Trust to Neutral

Related Posts

Apollo Endosurgery’s New Obesity Endoscopic Systems Receive FDA Nod

Immutep Announces GMP Manufacturing Process Developed For IMP761, A First-in-Class LAG-3 Agonist For Autoimmune Disease

Canaccord Genuity Maintains Buy on Open Lending, Lowers Price Target to $30

Morgan Stanley Maintains Overweight on Take-Two Interactive, Lowers Price Target to $195